UCSF Pediatric Diabetes Program Director Steve Gitelman, MD has partnered with the Immune Tolerance Network (ITN) to launch a study involving ATG , or anti-thymocyte globulin, to see if this drug can halt the progression of new onset type 1 diabetes.